Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.02 USD
-0.97%
Market Closed
Updated:
Jun 9, 2024
Adaptimmune Therapeutics PLC
Other Equity
|
Adaptimmune Therapeutics PLC
Other Equity Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Other Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Other Equity
-$2.7m
|
CAGR 3-Years
35%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Other Equity
$1.5m
|
CAGR 3-Years
146%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Other Equity
-$29m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Equity
-$778k
|
CAGR 3-Years
38%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Equity
-£36.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other Equity
£25.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
See Also
What is Adaptimmune Therapeutics PLC's Other Equity?
Other Equity
-2.7m
USD
-2.7m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Other Equity amounts to -2.7m USD.
What is Adaptimmune Therapeutics PLC's Other Equity growth rate?
Other Equity CAGR 5Y
27%
27%
Over the last year, the Other Equity growth was -109%. The average annual Other Equity growth rates for Adaptimmune Therapeutics PLC have been 35% over the past three years , 27% over the past five years .
You don't have any saved screeners yet
